Congenital heart disease

End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study

Eur Heart JPublished Retrospective cohort study

Authors' conclusion

Patients with ccTGA have variable deterioration to end-stage heart failure or death over time, commonly between their fifth and sixth decades. Predictors include arrhythmic and CHF events and severe RV dysfunction but not anatomy or need for tricuspid valve surgery.

Study context

Population
Adults with congenitally corrected transposition of the great arteries (ccTGA) seen at a congenital heart disease centremedian follow-up 8.7 years
Participants
558 adults
Outcome
Composite of:
  • Mechanical circulatory support
  • Heart transplantation
  • Death
Methodological detailsmulticentre
  • Multicentre

Main finding

As reported in the abstract

Composite primary outcome

Event rate of primary outcome

15.4 per 1000 person-years

Mechanical circulatory support implantations

11

Transplantations

12

Deaths

52

Observational data: associations, not effects.

Further findings

OutcomeModerate/severe RV dysfunction and tricuspid regurgitationMild/less RV dysfunction and tricuspid regurgitationP value
Primary outcome by RV dysfunction and tricuspid regurgitation severity31 of 11013 of 181P < 0.001

Anatomic complexity, prior tricuspid valve surgery, subpulmonic obstruction

Outcomes not different

Independent predictors of primary outcome (multivariable Cox regression)

Older age, prior congestive heart failure (CHF) admission and severe right ventricular (RV) dysfunction were independent predictors

Childhood surgery vs age- and sex-matched controls

More adverse outcomes after childhood surgery

Original publication

End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study. Eur Heart J. Published 18 August 2023. doi:10.1093/eurheartj/ehad511

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.